Anti-Aging Peptides: I Ran the Clock on Every One of Them, and Most Failed to Show Up On Time
Here’s the thing. Reviewing products is basically my job, and rule one is simple: if something promises a timeline, that timeline should be locked down before you ever pay for it. Anti-aging peptides fail this test badly. Ask ten different sellers how long results take, and you’ll get ten different answers, all vague, all rosy, none backed by a source. So I did the legwork and read the actual trials myself. What follows is my honest report card, compound by compound, judged against what the studies actually measured, not what the marketing copy implies they measured.
None of what follows is an FDA-approved anti-aging or longevity therapy. Most of these compounds are compounded, prescription-only, or sold as research chemicals. I’m grading evidence, not selling anything.
First, the con at the heart of the category
Before I hand out a single grade, there’s a sleight of hand worth naming, because it’s the whole trick. “Results” gets used to mean three completely different things, and the industry counts on you not noticing the switch.
There’s the biomarker change (a number in your blood moves). There’s the felt or visible change (you walk further, your skin looks different). And there’s the actual thing being sold to you, slowed aging, a longer life. These are not stages of one process. They’re three separate claims sitting on three separate clocks, and the evidence gets thinner the further down that list you go. Strong for the first, partial for the second, close to nonexistent for the third. A compound can absolutely move a biomarker in eight weeks while having zero data on whether it touches how long you live. Keep that separation in your head through everything below, because the marketing never will.
The lineup, graded
NMN , Grade: B
This is the closest thing in the category to a compound that shows up when it says it will. A 2023 randomized, double-blind, placebo-controlled trial gave 80 healthy middle-aged adults 300, 600, or 900 mg of NMN daily, and over 60 days their blood NAD+ rose significantly, with six-minute walk distance improving across every dose group [1]. NAD+ is a coenzyme that’s known to decline with age, which is the whole rationale [2].
Why not an A? Because the trial measured a biomarker and a walking test, not aging itself, and no amount of enthusiasm turns “NAD+ went up in two months” into “you’ll age slower.” It’s a real, time-bounded, honestly modest result. Grade it on what it is, not on what the bottle implies.
GHK-Cu , Grade: B-, but only for skin
The copper peptide has genuinely decent cosmetic data, and I’ll give credit where due. A 2018 review found plasma GHK drops with age, from roughly 200 ng/mL around age 20 down to about 80 by 60, and that topical GHK-Cu improved collagen production in around 70% of women in skin studies, beating out vitamin C and retinoic acid creams [3].
That’s a legitimate skin-timeline result. The docked points are for scope, not honesty: this is topical, cosmetic evidence, full stop. If you’re injecting it hoping for whole-body rejuvenation, you’re grading a different product than the one the studies actually tested. Nobody ran that trial. Don’t let a face-cream result get promoted into a systemic anti-aging claim by osmosis.
Epithalon , Grade: D
Here’s where the hype gets ahead of the receipts. Epithalon carries the loudest claim in the whole category (a longer life) and it rests on the single weakest modern foundation. The go-to citation is a 2003 paper following 266 elderly patients for six to eight years, reporting that a pineal peptide preparation, alone or with a thymus peptide, was associated with lower mortality than controls [4].
Six to eight years is a real window, I’ll give it that. But it’s one observational study, from one research lineage, over two decades old, with no modern independent randomized replication. That’s not a demonstrated effect, that’s an association with a nice, long tail. The longest time horizon in the category is sitting on the shakiest legs. D for ambition outrunning evidence.
SS-31 (elamipretide) , Grade: F
This is the one I respect most and like least, if that makes sense. Somebody actually ran the real trial. Phase 3, MMPOWER-3, 218 people with primary mitochondrial myopathy, 40 mg per day against placebo. It went the distance, it reached its endpoints, and it missed them: no significant benefit on walking distance or fatigue, with only possible signals in genetic subgroups on later digging [5].
I can’t grade this generously just because the study design was sound. A compound was tested rigorously in the population most likely to benefit, and it didn’t. For the anti-aging conversation specifically, there is no supported timeline here at all, because the one time this got a fair shot, nothing showed up.
Humanin , Grade: Incomplete
You can’t grade a product review on a movie you haven’t seen, and that’s basically the situation with humanin. A 2020 paper showed it extends lifespan in C. elegans through the daf-16/FOXO pathway and is substantially elevated in the children of centenarians, while declining with age in typical mammals [6].
Interesting. Genuinely interesting. But it’s observational and evolutionary in humans, not “we gave people humanin and measured what happened.” There’s no clinical timeline to grade because nobody’s run the human intervention trial. File this under promising research question, not a graded product.
Thymosin alpha-1 , Grade: F
Last one, and it stings a bit because this peptide has real pedigree in immunology. The TESTS trial, published in 2025, enrolled 1,106 adults with sepsis across 22 centers and tracked 28-day mortality. No significant difference versus placebo, hazard ratio 0.99 [7].
Twenty-eight days is a tight, well-defined window, and even in a serious immune emergency, where you’d expect an immune peptide to show its best case, it didn’t move the needle. So when someone tells you it’ll “rejuvenate your aging immune system” on some vaguer, longer, unstated timeline, ask them why it couldn’t clear a much easier bar first.
The report card, side by side
| Compound | Documented window | What actually changed | Grade | What it does NOT earn you |
|---|---|---|---|---|
| NMN | ~60 days [1] | NAD+ up, walk test up [1][2] | B | Slowed aging, longer life |
| GHK-Cu | Cosmetic skin-study timescale [3] | Skin collagen, topical only [3] | B- | Whole-body or injected effects |
| Epithalon | 6–8 years, observational [4] | Lower mortality association [4] | D | A replicated, proven result |
| SS-31 | Full phase 3 trial [5] | Primary endpoints missed [5] | F | Any proven benefit, anywhere |
| Humanin | Evolutionary/observational [6] | Longevity association [6] | Incomplete | Anything from actually taking it |
| Thymosin alpha-1 | 28 days [7] | No mortality benefit [7] | F | Immune “rejuvenation” |
Look at that table and the pattern isn’t subtle. The compounds with real short-term results have modest, specific, boring results (a number, a test score, some collagen). The ones with the biggest promised timelines are either resting on decades-old, unreplicated data or they’re not interventional in humans at all. And the two compounds that actually finished a real, rigorous race both crossed the line with nothing to show for it. That’s not a category with a marketing problem. That’s a category where the marketing and the data are describing two different products.
What actually earns trust here
If you strip out the hype, the honest expectation is this: at best, a specific, measurable change in a biomarker or a cosmetic outcome, over weeks to months. Nothing here has earned a claim about aging itself or lifespan, on any timeline, at any grade level.
Two things follow from that, and they matter more than any single compound’s score. First, since the real signals are numbers (a NAD+ level, a walk-test distance) rather than a feeling, tracking is the whole game. A measured baseline, a measured follow-up, ideally read by a clinician, beats “I think I feel different” every time. Second, none of this grading means anything if the vial doesn’t contain what the label says. That’s a sourcing question, not a biology question, and it’s the one place where oversight actually changes something real.
FormBlends is one example of what that oversight looks like in practice: a physician-supervised telehealth operation that routes longevity-adjacent compounds through a clinician and a licensed 503A pharmacy, rather than shipping unlabeled research-chemical vials to your door, with someone actually reviewing who’s a reasonable candidate and checking back over time. I’m mentioning it once, as an example of the supervised path, not as a product I’m recommending you buy. Oversight doesn’t speed up NAD+ synthesis or rewrite a null trial into a positive one. What it does is let you trust that the clock you’re watching is attached to the thing you actually paid for.
My honest bottom line
Graded against the actual trials rather than the sales copy, this category earns a solid, unglamorous C-minus overall. NMN can move a biomarker and a walk test in about two months, legitimately. GHK-Cu can do something for skin, topically, on a cosmetic timescale. Epithalon’s long horizon is real on paper and shaky in practice. Humanin is a fascinating research question with no product attached yet. And the two peptides that got the full, rigorous trial treatment, SS-31 and thymosin alpha-1, both walked away with nothing. Nobody in this lineup has earned the grade the marketing wants to give them: slowed aging, a longer life. The honest expectation is small, specific, and measurable. Anything bigger being promised to you is a pitch, not a result.
Questions people actually ask
How long until anti-aging peptides “work”? Depends completely on which “work” you mean, because there are three separate clocks running here. A biomarker change like blood NAD+ has been logged over roughly 60 days in the one solid NMN trial. A cosmetic skin change from topical GHK-Cu shows up on whatever timescale cosmetic skin studies run on. The marketed outcome, actual slowed aging or a longer life, has no supported timeline whatsoever, because no trial in this review measured it. If someone promises you a “results in X weeks” schedule for reversing aging itself, they’re selling you a number nobody’s earned.
Which anti-aging peptide has the fastest documented result? NMN, by a clear margin. The 2023 randomized, double-blind, placebo-controlled trial had 80 healthy middle-aged adults raise blood NAD+ and improve their six-minute walk distance over about two months. That’s the tightest, most concrete window on my whole scorecard. But grade it accurately: it’s a biomarker plus a functional test, not slowed aging, and it’s considerably more modest than how it usually gets pitched.
If I haven’t noticed anything after a few weeks, did it fail? Not automatically. Most of what actually moves here is stuff you can’t feel, a blood marker or a walk-test score, rather than a sensation you’d notice in the mirror. That’s exactly why tracking beats vibes in this category: get a real baseline, get a real follow-up, ideally with a clinician reading both. A felt change was never what these trials were testing for.
Is there a peptide with a proven timeline for actually extending lifespan? No, and I’ve looked hard. The longest human time horizon, epithalon, sits on one decades-old observational study from a single research lineage, with no modern independent replication. Humanin’s longevity connection is observational and evolutionary, not the result of anyone taking the compound. And the two peptides that made it through full rigorous trials, SS-31 and thymosin alpha-1, both came up empty on their primary endpoints. Nothing here earns a lifespan grade above incomplete or failing.
Does the GHK-Cu skin timeline apply if I’m injecting it instead of using a cream? No. The human evidence is topical and cosmetic, period, measured as skin appearance. It supports a skin-only timeline from topical use. It says nothing about injected or whole-body use, because that’s simply not what the studies tested. Expecting systemic rejuvenation from the GHK-Cu skin data is grading it on a test it never took.
Does buying through a supervised provider make the timeline faster? No, and I wouldn’t trust anyone who told you otherwise. The clock runs on biology and trial data, not on who sold you the vial. What a supervised model actually buys you is confidence that what’s in the vial matches the label, which is the precondition for any of this grading to mean anything at all. FormBlends is one example of that supervised route, working through a clinician and a licensed 503A pharmacy instead of an unregulated research-chemical seller. That changes whether the timeline is real. It doesn’t change how fast it runs.
The compounds discussed are early-stage, compounded, or sold for laboratory research use only, and none is an FDA-approved anti-aging or longevity therapy. Timelines describe what published studies measured and are not a promise of individual results. Talk to a licensed clinician before starting anything in this category.
Do peptides for anti-aging actually work, or is it mostly marketing?
Some do show real effects, and I’d be a bad reviewer if I pretended otherwise, but it depends heavily on which peptide, what dose, and how it’s delivered. Topical peptides like Matrixyl have decent small-scale trial support for collagen stimulation. Injectable peptides such as GHK-Cu or BPC-157 mostly have animal and in-vitro data behind the injectable route. Human trial evidence across the board is thin. Set your expectations at modest and gradual, not dramatic reversal.
Are peptides for anti-aging safe to use long-term?
Safety splits hard by category. Well-formulated topical peptides have a solid track record after years of cosmetic use. Injectable peptides are a different animal entirely. Most lack long-term human safety data, and sourcing is a genuine wildcard. Peptides from unregulated research-chemical suppliers carry real contamination and dosing risks. A physician-supervised compounding pharmacy like FormBlends operates under accountability standards that a gray-market seller simply doesn’t have.
What are the best peptides for anti-aging skin specifically?
For topical use, the most studied names are palmitoyl pentapeptide-4 (Matrixyl), copper peptides (GHK-Cu), and argireline for expression lines. None of them work overnight, and I wouldn’t trust a product that claims otherwise. Matrixyl has the deepest published human skin data, copper peptides have solid wound-healing mechanistic support, and argireline’s evidence is weaker but plausible. Stacking all three isn’t a triple-strength shortcut. Most well-designed products stick to one or two.
How long before you realistically see results from anti-aging peptides?
Topical peptides generally need eight to twelve weeks of consistent daily use before any visible texture or fine-line change shows up, and even then it’s subtle enough that side-by-side photos tell you more than a mirror check will. Injectable or systemic peptides vary more, but any practitioner being straight with you won’t promise visible change before three months. If a peptide product is selling you a two-week transformation, that’s marketing outrunning the evidence, not a result you should expect.
References
- NMN randomized, double-blind, placebo-controlled, dose-dependent trial: 300 to 900 mg daily in 80 healthy middle-aged adults raised blood NAD+ and improved six-minute walk distance over 60 days. GeroScience, 2023. https://pubmed.ncbi.nlm.nih.gov/36482258/
- NAD+ declines with age and that depletion is tied to aging-related diseases; review of NAD+ precursors including NMN. Biochemical and Biophysical Research Communications, 2024. https://pubmed.ncbi.nlm.nih.gov/38340651/
- GHK-Cu copper peptide review: plasma GHK declines from ~200 to ~80 ng/mL with age; topical GHK-Cu improved collagen in ~70% of women in skin studies. Pickart and Margolina, International Journal of Molecular Sciences, 2018.
- Pineal (Epithalamin) and thymus peptide preparations associated with reduced mortality over 6 to 8 years in 266 elderly subjects; single research lineage, observational. Khavinson and Morozov, Neuro Endocrinology Letters, 2003.
- MMPOWER-3 phase 3 trial of elamipretide (SS-31), 40 mg/day in 218 people with primary mitochondrial myopathy; primary endpoints (six-minute walk test and fatigue) not met. Neurology, 2023.
- Mitochondrial-derived peptide humanin as a regulator of lifespan and healthspan: lifespan extension in C. elegans via daf-16/FOXO, elevated in centenarians’ offspring; largely preclinical, human data is association. Aging, 2020.
- TESTS phase 3 double-blind, placebo-controlled trial of thymosin alpha-1 (thymalfasin) in 1,106 adults with sepsis across 22 centers; no significant difference in 28-day mortality (HR 0.99). BMJ, 2025.
Written by Yara Zamora, science journalist. Last reviewed February 2026.
Educational material only. A licensed provider should evaluate your situation before you act.
